Lucid Diagnostics receives VA contract for esophageal cancer test

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced it received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. The contract expands access to esophageal precancer testing across the VA healthcare system, which serves more than nine million enrolled veterans annually.

The contract operates under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate set by the Centers for Medicare & Medicaid Services. This arrangement allows VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

"We are proud to partner with the U.S. Department of Veterans Affairs to expand access to EsoGuard for our nation's veterans," said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics. "The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard."

Lucid Diagnostics is a commercial-stage medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM). The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer. The EsoGuard test is performed on samples collected through a brief office procedure using the company's EsoCheck Esophageal Cell Collection Device.

The information is based on a press release statement from the company.

You May Also Be Interested In

• OSI Systems wins $85M CBP contract for mobile X-ray systems
• Cosmos Health posts 29% revenue rise but widens net loss in Q2 2026
• Nasus Pharma CFO departs, interim replacement named